261 related articles for article (PubMed ID: 29659889)
21. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
Ciencewicki JM; Herbert AS; Storm N; Josleyn NM; Huie KE; McKay LGA; Griffiths A; Dye JM; Willis T; Arora V
J Infect Dis; 2022 Feb; 225(4):733-740. PubMed ID: 34448858
[TBL] [Abstract][Full Text] [Related]
22. Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay.
Anderson MS; Niemuth NA; Sabourin CL; Badorrek CS; Bounds CE; Rudge TL
PLoS One; 2020; 15(8):e0238196. PubMed ID: 32841291
[TBL] [Abstract][Full Text] [Related]
23. Molecular Evidence of Sexual Transmission of Ebola Virus.
Mate SE; Kugelman JR; Nyenswah TG; Ladner JT; Wiley MR; Cordier-Lassalle T; Christie A; Schroth GP; Gross SM; Davies-Wayne GJ; Shinde SA; Murugan R; Sieh SB; Badio M; Fakoli L; Taweh F; de Wit E; van Doremalen N; Munster VJ; Pettitt J; Prieto K; Humrighouse BW; Ströher U; DiClaro JW; Hensley LE; Schoepp RJ; Safronetz D; Fair J; Kuhn JH; Blackley DJ; Laney AS; Williams DE; Lo T; Gasasira A; Nichol ST; Formenty P; Kateh FN; De Cock KM; Bolay F; Sanchez-Lockhart M; Palacios G
N Engl J Med; 2015 Dec; 373(25):2448-54. PubMed ID: 26465384
[TBL] [Abstract][Full Text] [Related]
24. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
25. Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma.
Spengler JR; McElroy AK; Harmon JR; Ströher U; Nichol ST; Spiropoulou CF
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S346-9. PubMed ID: 25941333
[TBL] [Abstract][Full Text] [Related]
26. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
27. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
28. Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.
Houlihan CF; McGowan CR; Dicks S; Baguelin M; Moore DAJ; Mabey D; Roberts CH; Kumar A; Samuel D; Tedder R; Glynn JR
PLoS Med; 2017 May; 14(5):e1002300. PubMed ID: 28510604
[TBL] [Abstract][Full Text] [Related]
29. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea.
Fischer K; Camara A; Troupin C; Fehling SK; Strecker T; Groschup MH; Tordo N; Diederich S
Transbound Emerg Dis; 2020 Mar; 67(2):724-732. PubMed ID: 31627257
[TBL] [Abstract][Full Text] [Related]
30. Minimally Symptomatic Infection in an Ebola 'Hotspot': A Cross-Sectional Serosurvey.
Richardson ET; Kelly JD; Barrie MB; Mesman AW; Karku S; Quiwa K; Marsh RH; Koedoyoma S; Daboh F; Barron KP; Grady M; Tucker E; Dierberg KL; Rutherford GW; Barry M; Jones JH; Murray MB; Farmer PE
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005087. PubMed ID: 27846221
[TBL] [Abstract][Full Text] [Related]
31. The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field.
van Griensven J; De Weiggheleire A; Delamou A; Smith PG; Edwards T; Vandekerckhove P; Bah EI; Colebunders R; Herve I; Lazaygues C; Haba N; Lynen L
Clin Infect Dis; 2016 Jan; 62(1):69-74. PubMed ID: 26261205
[TBL] [Abstract][Full Text] [Related]
32. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
[TBL] [Abstract][Full Text] [Related]
33. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.
Macneil A; Reed Z; Rollin PE
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1175. PubMed ID: 21666792
[TBL] [Abstract][Full Text] [Related]
34. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
35. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.
Gunn BM; Roy V; Karim MM; Hartnett JN; Suscovich TJ; Goba A; Momoh M; Sandi JD; Kanneh L; Andersen KG; Shaffer JG; Schieffelin JS; Garry RF; Grant DS; Alter G
J Infect Dis; 2020 Jan; 221(1):156-161. PubMed ID: 31301137
[TBL] [Abstract][Full Text] [Related]
36. Lateral Flow Immunoassays for Ebola Virus Disease Detection in Liberia.
Phan JC; Pettitt J; George JS; Fakoli LS; Taweh FM; Bateman SL; Bennett RS; Norris SL; Spinnler DA; Pimentel G; Sahr PK; Bolay FK; Schoepp RJ
J Infect Dis; 2016 Oct; 214(suppl 3):S222-S228. PubMed ID: 27443616
[TBL] [Abstract][Full Text] [Related]
37. Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins.
Groen J; van den Hoogen BG; Burghoorn-Maas CP; Fooks AR; Burton J; Clegg CJ; Zeller H; Osterhaus AD
Microbes Infect; 2003 Apr; 5(5):379-85. PubMed ID: 12737993
[TBL] [Abstract][Full Text] [Related]
38. Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque.
Alfson KJ; Avena LE; Worwa G; Carrion R; Griffiths A
Viruses; 2017 Oct; 9(11):. PubMed ID: 29109373
[TBL] [Abstract][Full Text] [Related]
39. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
[TBL] [Abstract][Full Text] [Related]
40. A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay.
Singh K; Marasini B; Chen X; Spearman P
J Immunol Methods; 2018 Sep; 460():10-16. PubMed ID: 29894746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
